title: Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients.
authors.forename: Rafael A
authors.initials: RA
authors.lastname: Navascués
authors.forename: Ernesto
authors.initials: E
authors.lastname: Gómez
authors.forename: Minerva
authors.initials: M
authors.lastname: Rodriguez
authors.forename: Ana S
authors.initials: AS
authors.lastname: Laures
authors.forename: Jose
authors.initials: J
authors.lastname: Baltar
authors.forename: Jaime A
authors.initials: JA
authors.lastname: Grande
mesh_terms: D000328:Adult; D000493:Allopurinol / Q000009:adverse effects* / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood*
chemical_list: D007166:Immunosuppressive Agents; D014527:Uric Acid; D000493:Allopurinol; D016572:Cyclosporine; D009173:Mycophenolic Acid